Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS)
CNY 9.37
(-0.85%)
CNY 9.37
(-0.85%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 734.44 Million CNY | 8.74% |
| 2022 | 675.39 Million CNY | -9.53% |
| 2021 | 746.55 Million CNY | -24.81% |
| 2020 | 992.94 Million CNY | 17.97% |
| 2019 | 841.66 Million CNY | -2.65% |
| 2018 | 864.59 Million CNY | 76.34% |
| 2017 | 490.3 Million CNY | 26.56% |
| 2016 | 387.4 Million CNY | 9.35% |
| 2015 | 354.28 Million CNY | 56.31% |
| 2014 | 226.64 Million CNY | 106.04% |
| 2013 | 110 Million CNY | 124.49% |
| 2012 | 49 Million CNY | -42.5% |
| 2011 | 85.22 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 518.9 Million CNY | -2.18% |
| 2024 Q1 | 783.3 Million CNY | 6.65% |
| 2024 Q2 | 530.48 Million CNY | -32.28% |
| 2023 FY | 734.44 Million CNY | 8.74% |
| 2023 Q2 | 553.55 Million CNY | -28.26% |
| 2023 Q3 | 814.83 Million CNY | 47.2% |
| 2023 Q4 | 734.44 Million CNY | -9.87% |
| 2023 Q1 | 771.64 Million CNY | 14.25% |
| 2022 Q1 | 741.59 Million CNY | -0.66% |
| 2022 Q2 | 730.61 Million CNY | -1.48% |
| 2022 Q4 | 675.39 Million CNY | -10.4% |
| 2022 Q3 | 753.74 Million CNY | 3.17% |
| 2022 FY | 675.39 Million CNY | -9.53% |
| 2021 FY | 746.55 Million CNY | -24.81% |
| 2021 Q1 | 1.03 Billion CNY | 4.37% |
| 2021 Q2 | 888.28 Million CNY | -14.29% |
| 2021 Q3 | 863.76 Million CNY | -2.76% |
| 2021 Q4 | 746.55 Million CNY | -13.57% |
| 2020 Q1 | 844.85 Million CNY | 0.38% |
| 2020 FY | 992.94 Million CNY | 17.97% |
| 2020 Q2 | 940.03 Million CNY | 11.27% |
| 2020 Q4 | 992.94 Million CNY | 9.53% |
| 2020 Q3 | 906.52 Million CNY | -3.56% |
| 2019 Q2 | 750.64 Million CNY | -12.67% |
| 2019 Q1 | 859.59 Million CNY | -0.58% |
| 2019 FY | 841.66 Million CNY | -2.65% |
| 2019 Q4 | 841.66 Million CNY | 10.33% |
| 2019 Q3 | 762.83 Million CNY | 1.62% |
| 2018 Q1 | 487.3 Million CNY | -0.61% |
| 2018 FY | 864.59 Million CNY | 76.34% |
| 2018 Q4 | 864.59 Million CNY | 98.44% |
| 2018 Q3 | 435.7 Million CNY | -2.24% |
| 2018 Q2 | 445.7 Million CNY | -8.54% |
| 2017 FY | 490.3 Million CNY | 26.56% |
| 2017 Q1 | 467.4 Million CNY | 20.65% |
| 2017 Q2 | 620.9 Million CNY | 32.84% |
| 2017 Q3 | 548.6 Million CNY | -11.64% |
| 2017 Q4 | 490.3 Million CNY | -10.63% |
| 2016 Q3 | 430 Million CNY | 2.87% |
| 2016 Q1 | 369.7 Million CNY | 4.35% |
| 2016 Q2 | 418 Million CNY | 13.06% |
| 2016 Q4 | 387.4 Million CNY | -9.91% |
| 2016 FY | 387.4 Million CNY | 9.35% |
| 2015 Q1 | - CNY | -100.0% |
| 2015 FY | 354.28 Million CNY | 56.31% |
| 2015 Q3 | 373.61 Million CNY | 0.0% |
| 2015 Q4 | 354.28 Million CNY | -5.17% |
| 2014 Q4 | 226.64 Million CNY | 0.0% |
| 2014 FY | 226.64 Million CNY | 106.04% |
| 2013 FY | 110 Million CNY | 124.49% |
| 2012 FY | 49 Million CNY | -42.5% |
| 2011 FY | 85.22 Million CNY | 0.0% |